What is Alimetry?
Alimetry specializes in innovative gastric diagnostics, offering the Gastric Alimetry system, a medical device designed for Body Surface Gastric Mapping to aid in diagnosing various gastric disorders. Their solutions provide clinicians with data-driven insights into gastric function, motility, and electrophysiology, particularly for patients experiencing chronic gastric symptoms. The company serves healthcare facilities in the United States, United Kingdom, and New Zealand, focusing on enhancing patient care through advanced diagnostic tools. Alimetry aims to empower clinicians with clear treatment pathways and tailored management strategies for complex gastric conditions.
How much funding has Alimetry raised?
Alimetry has raised a total of $18M across 1 funding round:
Series A
$18M
Series A (2024): $18M with participation from GD1 (Global From Day One, American Gastroenterological Association, and Icehouse Ventures
Key Investors in Alimetry
GD1 (Global From Day One)
Global From Day One (GD1) is a venture capital firm that invests in high-growth technology companies originating from New Zealand, focusing on founders and teams poised to compete in major global markets.
American Gastroenterological Association
The American Gastroenterological Association (AGA) is dedicated to improving digestive health by empowering clinicians and researchers through educational resources and research funding.
Icehouse Ventures
Icehouse Ventures is an early-stage venture firm with significant assets under management, committed to backing New Zealand founders to build world-class companies and create long-term value.
What's next for Alimetry?
With the successful closure of this major enterprise-level funding, Alimetry is set to scale its operational footprint and deepen its clinical research initiatives. The strategic roadmap likely involves expanding the adoption of the Gastric Alimetry system within major hospital networks and integrating the platform into standard clinical workflows for gastroenterology. By focusing on data-driven patient outcomes, the company is poised to disrupt traditional diagnostic paradigms, potentially setting a new standard for how complex gastric conditions are identified and managed globally. Future growth will likely be characterized by increased investment in R&D to further refine their electrophysiological mapping capabilities and broaden their diagnostic portfolio.
See full Alimetry company page
